170 related articles for article (PubMed ID: 27635947)
21. Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto-oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal.
Prazeres HJ; Rodrigues F; Figueiredo P; Naidenov P; Soares P; Bugalho MJ; Lacerda M; Campos B; Martins TC
Clin Endocrinol (Oxf); 2006 Jun; 64(6):659-66. PubMed ID: 16712668
[TBL] [Abstract][Full Text] [Related]
22. A Novel Double
Mathew A; Latteyer S; Frank-Raue K; Moeller LC; Zwanziger D; Mengel M; Führer D; Tiedje V
Thyroid; 2021 Feb; 31(2):327-329. PubMed ID: 32546069
[No Abstract] [Full Text] [Related]
23. RET genetic screening in patients with medullary thyroid cancer: the Moroccan experience.
Abdelhakim A; Barlier A; Kebbou M; Benabdeljalil N; Timinouni M; Taoufiq F; Roche C; El Antri S
J Cancer Res Ther; 2009; 5(3):198-202. PubMed ID: 19841562
[TBL] [Abstract][Full Text] [Related]
24. Detecting N-RAS Q61R Mutated Thyroid Neoplasias by Immunohistochemistry.
Crescenzi A; Fulciniti F; Bongiovanni M; Giovanella L; Trimboli P
Endocr Pathol; 2017 Mar; 28(1):71-74. PubMed ID: 28064410
[TBL] [Abstract][Full Text] [Related]
25. Hereditary Medullary Thyroid Cancer Genotype-Phenotype Correlation.
Frank-Raue K; Raue F
Recent Results Cancer Res; 2015; 204():139-56. PubMed ID: 26494387
[TBL] [Abstract][Full Text] [Related]
26. NRAS (Q61R), BRAF (V600E) immunohistochemistry: a concomitant tool for mutation screening in melanomas.
Uguen A; Talagas M; Costa S; Samaison L; Paule L; Alavi Z; De Braekeleer M; Le Marechal C; Marcorelles P
Diagn Pathol; 2015 Jul; 10():121. PubMed ID: 26204954
[TBL] [Abstract][Full Text] [Related]
27. Medullary thyroid carcinoma: pitfalls in diagnosis by fine needle aspiration cytology and relationship of cytomorphology to RET proto-oncogene mutations.
Chang TC; Wu SL; Hsiao YL
Acta Cytol; 2005; 49(5):477-82. PubMed ID: 16334022
[TBL] [Abstract][Full Text] [Related]
28. Detection of Molecular Alterations in Medullary Thyroid Carcinoma Using Next-Generation Sequencing: an Institutional Experience.
Wei S; LiVolsi VA; Montone KT; Morrissette JJ; Baloch ZW
Endocr Pathol; 2016 Dec; 27(4):359-362. PubMed ID: 27379493
[TBL] [Abstract][Full Text] [Related]
29. Identification of Driving ALK Fusion Genes and Genomic Landscape of Medullary Thyroid Cancer.
Ji JH; Oh YL; Hong M; Yun JW; Lee HW; Kim D; Ji Y; Kim DH; Park WY; Shin HT; Kim KM; Ahn MJ; Park K; Sun JM
PLoS Genet; 2015 Aug; 11(8):e1005467. PubMed ID: 26295973
[TBL] [Abstract][Full Text] [Related]
30. Hereditary medullary thyroid cancer in Slovenia--genotype-phenotype correlations.
Bergant D; Hocevar M; Besic N; Glavac D; Korosec B; Caserman S
Wien Klin Wochenschr; 2006 Jul; 118(13-14):411-6. PubMed ID: 16865646
[TBL] [Abstract][Full Text] [Related]
31. NRASQ61R immunohistochemistry detects both NRASQ61R and KRASQ61R mutations in colorectal cancer.
Jhuang JY; Yuan CT; Lin YL; Cheng ML; Liau JY; Tsai JH
Pathology; 2017 Jun; 49(4):387-390. PubMed ID: 28433252
[TBL] [Abstract][Full Text] [Related]
32. Genetic testing in multiple endocrine neoplasia and related syndromes.
Calender A
Forum (Genova); 1998; 8(2):146-59. PubMed ID: 9666051
[TBL] [Abstract][Full Text] [Related]
33. Medullary Thyroid Carcinoma in Children.
Graves CE; Gosnell JE
Semin Pediatr Surg; 2020 Jun; 29(3):150921. PubMed ID: 32571506
[TBL] [Abstract][Full Text] [Related]
34. [Clinical characteristics of multiple endocrine neoplasia].
Conte-Devolx B; Niccoli P;
Bull Acad Natl Med; 2010 Jan; 194(1):69-78; discussion 78-9. PubMed ID: 20669560
[TBL] [Abstract][Full Text] [Related]
35. The development of rapid and accurate screening test for RET hotspot somatic and germline mutations in MEN2 syndromes.
Zupan A; Glavač D
Exp Mol Pathol; 2015 Dec; 99(3):416-25. PubMed ID: 26321248
[TBL] [Abstract][Full Text] [Related]
36. mTOR activation in medullary thyroid carcinoma with RAS mutation.
Lyra J; Vinagre J; Batista R; Pinto V; Prazeres H; Rodrigues F; Eloy C; Sobrinho-Simões M; Soares P
Eur J Endocrinol; 2014 Nov; 171(5):633-40. PubMed ID: 25163725
[TBL] [Abstract][Full Text] [Related]
37. Multiple endocrine neoplasia, the old and the new: a mini review.
Pasquali D; Di Matteo FM; Renzullo A; Accardo G; Esposito D; Barbato F; Colantuoni V; Circelli L; Conzo G
G Chir; 2012; 33(11-12):370-3. PubMed ID: 23140918
[TBL] [Abstract][Full Text] [Related]
38. RAS proto-oncogene in medullary thyroid carcinoma.
Moura MM; Cavaco BM; Leite V
Endocr Relat Cancer; 2015 Oct; 22(5):R235-52. PubMed ID: 26285815
[TBL] [Abstract][Full Text] [Related]
39. RET mutation screening in MEN2 patients and discovery of a novel mutation in a sporadic medullary thyroid carcinoma.
Jhiang SM; Fithian L; Weghorst CM; Clark OH; Falko JM; O'Dorisio TM; Mazzaferri EL
Thyroid; 1996 Apr; 6(2):115-21. PubMed ID: 8733882
[TBL] [Abstract][Full Text] [Related]
40. C-cell hyperplasia and medullary thyroid carcinoma: clinicopathological and genetic correlations in 66 consecutive patients.
Guyétant S; Josselin N; Savagner F; Rohmer V; Michalak S; Saint-André JP
Mod Pathol; 2003 Aug; 16(8):756-63. PubMed ID: 12920219
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
